My ePortfolio Register   

Chemo-genomic interrogation reveals JAK sensitive subgroup in AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.16
Views: 1763

Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada

Dr Lavallée talks to ecancertv at EHA 2016 about a subtype of patients with acute myeloid leukaemia expressing CEBPA mutations.

He explains the further screening this subgroup through genomic and chemical screening to identify a cohort who express CSF3R mutations, which are sensitive to JAK inhibitors.

Dr Lavallée details these genes' frequency and overall genomic environment, how sensitivity to JAK inhibitors could inform treatment development and selection, as well as the overall importance of incorporating transcriptome data into research

ecancer's filming at EHA 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence